Tocvan Ventures Corp. (CSE:TOC) (CNSX:TOC.CN) (“Tocvan” or the “Corporation”) is pleased to announce final drill results from its Phase II drill program (the “Program”) at the Pilar Gold-Silver Project in Sonora, Mexico. A Phase II drill program was completed in June with over 3,500 meters of reverse circulation (RC) drilling in twenty (20) drill holes. Final results are included in this release, highlighted by drill hole JES-21-50 which returned 39.7 meters at 0.96 g/t Au in a 50 meter step-out to the Main Zone on trend with drill hole JES-21-47 which intersected 47.3 meters at 0.75 g/t Au. In addition, the first reconnaissance drill hole at the Triple Vein Zone (TVZ) was completed 400 meters to the east (JES-21-56) and was successful in intersecting mineralization at depth, returning 1.5 meters at 0.6 g/t Au and 139 g/t Ag.
Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is extremely pleased to issue partial results from human clinical study HYPER-H21-1 evaluating DehydraTECHTM-processed cannabidiol (“CBD”) for potential application against hypertension. Partial results related to blood pressure (“BP”) are being released today, while additional BP subset analyses and all other data analyses including pharmacokinetic (“PK”) evaluations and detailed blood chemistry work is in progress and will be released when complete.